WELCOME TO The PHARMACEUTICAL REPORT
The financialisation of Big Pharma
I'm For Real
Enter your details once to access all our information and resources
RAA provides invention to approval regulatory consulting in toxicology, formulation, clinical trial management, manufacturing, engineering, and business planning.
whitePaper | April 7, 2020
The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.
whitePaper | January 1, 2020
With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide.
Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.
whitePaper | April 7, 2022
The United States defines a rare disease as a condition affecting fewer than 200,000 people in the
country or one in which “there is no reasonable expectation” of recovering research and
development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis,
and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy
whitePaper | July 29, 2021
As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.
whitePaper | December 12, 2019
X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.
whitePaper | April 7, 2021
In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges.
One solution for these challenges is to engage HCPs – virtually.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE